Orally dissolving pilocarpine tablets for xerostomia in advanced cancer: A pilot N-of-1 feasibility study
Palliative Medicine · 2025-02 · 39 (2) · 298-306
DOI: 10.1177/02692163241306269 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Palliative Medicine, online erschienen am 24.12.2024. Verfasst von Karyn Foster und 6 weiteren Autor:innen. Beteiligte Einrichtung: Palliative and Supportive Care, Mater Misericordiae Ltd., South Brisbane, QLD, Australia. Hauptthemen laut MEDLINE: Pilocarpine, Xerostomia, Neoplasms, Muscarinic Agonists. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Mater Foundation.
Abstract (Originalsprache)
Background
Xerostomia is a common and difficult symptom experienced by patients with cancer. Pilocarpine is a cholinergic agent that stimulates salivation.
Aim
To assess the feasibility of conducting a N-of-1 trial to determine the efficacy of pilocarpine orally dissolving tablets in patients with xerostomia.
Design
Double-blind, crossover, placebo-controlled N-of-1 trials of 5 mg pilocarpine tablets vs placebo. Each trial consisted of three 6-day cycles containing pilocarpine (3 days) and placebo (3 days) in random order. Setting/participants: Participants with advanced cancer and xerostomia (scoring >3 on an 11-point numerical rating scale) from any cause, were recruited from an inpatient and outpatient palliative care unit in Brisbane, Australia.
Results
Eighteen people were recruited in 17 months. Nine withdrew, seven before or during the first 4 days. Three withdrew due to unacceptable side effects. Two participants met the definition of response (⩾2 point reduction in mean scores active vs placebo cycles). When assessing individual cycles, 15 out of 27 cycles (56%) met the definition of response. More people reported at least one mild episode during pilocarpine than placebo of nausea (6 vs 3), vomiting (3 vs 0) and sweating (3 vs 2). About 48% of adverse event classifications were reported in placebo cycles only.
Conclusion
Recruitment to an N-of-1 trial for xerostomia is feasible but attrition was high (50%). Early dropout may have been due to the trial length, complexity, appropriateness or number of questionnaires. Adverse events were generally mild. Two of 10 participants were considered to have benefited from pilocarpine warranting ongoing treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Palliative and Supportive Care, Mater Misericordiae Ltd., South Brisbane, QLD, Australia.
- Palliative and Supportive Care Research, Mater Research Institute, University of Queensland, South Brisbane, QLD, Australia.
- General Practice and Palliative Care, University of Queensland, Brisbane, QLD, Australia.
- School of Pharmacy, University of Queensland, Brisbane, QLD, Australia.
- School of Health Sciences, College of Health Massey University, Auckland, New Zealand.
ORCID-Profile: Karyn Foster, Janet Hardy
Förderung
- Mater Foundation
Zitieren
APA
Foster, K., Mitchell, G., Richard, E., Steadman, K. J., Senior, H., Estafanos, R., & Hardy, J. (2025). Orally dissolving pilocarpine tablets for xerostomia in advanced cancer: A pilot N-of-1 feasibility study. Palliative Medicine, 39(2), 298-306. https://doi.org/10.1177/02692163241306269
Vancouver
Foster K, Mitchell G, Richard E, Steadman KJ, Senior H, Estafanos R, et al. Orally dissolving pilocarpine tablets for xerostomia in advanced cancer: A pilot N-of-1 feasibility study. Palliative Medicine. 2025;39(2):298-306. doi:10.1177/02692163241306269
BibTeX
@article{Foster2025,
author = {Foster, Karyn and Mitchell, Geoff and Richard, Evan and Steadman, Kathryn J and Senior, Hugh and Estafanos, Rose and Hardy, Janet},
title = {Orally dissolving pilocarpine tablets for xerostomia in advanced cancer: A pilot N-of-1 feasibility study},
journal = {Palliative Medicine},
year = {2025},
volume = {39},
number = {2},
pages = {298--306},
doi = {10.1177/02692163241306269}
}
EUVIMED